author-photo

Lesley A. Mathews Griner

Novartis

7

Papers

65

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

2019 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (14)
Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (15)
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

2018 Journal of Visualized Experiments
Show All
- Source
- Cite
- Save
Citations (5)
Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers

2017 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (25)
Abstract 330: Development of a highly selective B/CRAF kinase inhibitor that exhibits antitumor activities in RAS and BRAF mutant tumors with minimal paradoxical activation

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)